TNF and COVID-19: Whether these therapies influence COVID-19 outcomes remains a pertinent question; the current literature suggests that TNF-α inhibitors may reduce the risk of severe outcomes by modulating hyperinflammatory states, a hypothesis that aligns with the cytokine-driven pathogenesis of both axSpA and severe COVID-19 [6,31,46,97,98,99].